大家都在搜
手机验证
优利科(上海)生命科学有限公司
100
详询
科研
/
多克隆
详见说明书
1年
Anti-eIF4E
eIF4E抗体
详询
兔
/
KLH conjugated synthetic peptide derived from human eIF4E
IgG
Lyophilized or Liquid
WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
-20℃
1mg/ml
详询
英文名称 Anti-eIF4E |
中文名称 真核翻译起始因子4E抗体 |
别 名 EIF4F; eIF-4E; eIF 4E; CBP; eIF 4F 25 kDa subunit; CBP; eIF 4E; eIF 4F 25 kDa subunit; EIF 4F; EIF4E1; EIF4EL1; EIF4F; Eukaryotic Translation Initiation Factor 4 E; Eukaryotic translation initiation factor 4E like 1; Messanger RNA Cap Binding Protein eIF 4E. |
浓 度 1mg/1ml |
规 格 0.1ml/100μg 0.2ml/200μg |
抗体来源 Rabbit |
克隆类型 polyclonal |
交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Daniorerio |
产品类型 一抗 |
研究领域 肿瘤 免疫学 信号转导 细胞凋亡 转录调节因子 表观遗传学 |
蛋白分子量 predicted molecular weight: 24kDa |
性 状 Lyophilized or Liquid |
免 疫 原 KLH conjugated synthetic peptide derived from human eIF4E |
亚 型 IgG |
纯化方法 affinity purified by Protein A |
储 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide |
产品应用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
(石蜡切片需做抗原修复) |
not yet tested in other applications. |
optimal dilutions/concentrations should be determined by the end user. |
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
产品介绍 eIF4E, a protein modulates translation of maternal mRNAs in early embryos before the onset of zygotic transcription. eIF4E also influences the overall rate of translation. eIF4E binds to the 7 methyl GTP cap structure of eukaryotic mRNAs. Phosphorylation of eIF4E on serine 209 regulates the affinity of this protein for the 7 methyl GTP cap and/or RNA. Phosphorylation also enhances the interaction of eIF4E with eIF4G, which form a complex known as eIF4F. eIF4E phosphorylation is correlated with increased translational rate in a number of cell types. Several kinases are currently being investigated as potential regulators of eIF4E including PKC and/or the MAP kinase activated Mnk. |
Function : Its translation stimulation activity is repressed by binding to the complex CYFIP1-FMR1 (By similarity). Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap. |
Subunit : eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. EIF4E is also known to interact with other partners. The interaction with EIF4ENIF1 mediates the import into the nucleus. Nonphosphorylated EIF4EBP1, EIF4EBP2 and EIF4EBP3 compete with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. Rapamycin can attenuate insulin stimulation, mediated by FKBPs. Interacts mutually exclusive with EIF4A1 or EIF4A2. Interacts with NGDN and PIWIL2. Component of the CYFIP1-EIF4E-FMR1 complex composed of CYFIP, EIF4E and FMR1. Interacts directly with CYFIP1 (By similarity). Interacts with Lassa virus Z protein. Binds to MKNK2 in nucleus. Interacts with LIMD1, WTIP and AJUBA. |
Subcellular Location : Cytoplasm, P-body. |
Post-translational modifications : Phosphorylation increases the ability of the protein to bind to mRNA caps and to form the eIF4F complex. |
Similarity : Belongs to the eukaryotic initiation factor 4E family. |
Database links : UniProtKB/Swiss-Prot: P06730.2 |
真核细胞翻译起始因子4E-EIF4E是蛋白合成的一个主要调控因子,它表达量增加会促进多种肿瘤的生长的增值、分化,因此EIF4E是一种非常重要的抗癌药物靶标。eIF-4E是一种涉及核糖体与mRNA帽子结构结合的真核生物翻译起始因子。它以2种形式存在:游离形式(25kDa)和作为多蛋白复合物eIF-4F的一个组分。 eIF-4E 是数量最少的一种起始因子,涉及翻译起始的限速步骤,磷酸化调节蛋白质的生物合成。 |
Anti-TTF-1 (Thyroid Transcription Factor-1) 甲状腺核转录因子-1/甲状腺特异增强子结合蛋白抗体 |
Anti-TTF-2(thyroid transcription factor 2;forkhead box E1) 甲状腺转录因子-2抗体 |
Anti-Tubulin-α 微管蛋白抗体 |
Anti-Tubulin-β 微管蛋白(免疫组化用抗体) |
Anti-Tubulin-β 微管蛋白抗体 |
Anti-Tubulin-γ 微管蛋白-γ抗体 |
Anti-TY3H/TH (Tyrosine Hydroxylase ) 酪氨酸羟化酶抗体 |
Anti-Tyrosinase 酪氨酸酶抗体 |
Anti-Tβ10 (thymosin β10) 胸腺素β10抗体 |
Anti-UAT (Urate transporter/channel) 尿酸盐转运子抗体 |
Anti-VAP1 (vascular adhesion protein 1) 血管粘附蛋白1抗体 |
Anti-VCAM-1/CD106 (Vascuolar cell adhesion molecule 1) 血管内皮细胞粘附分子抗体 |
Anti-VEGF(Vascuoar endothelial growth factor) 血管内皮生长因子抗体 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
抗体使用小技巧.docx 附 (下载 0 次)